Company news

June 2016

Senior Representatives of Curadev were available at:

  • ASCO, Chicago, Il between June 03-June 07 2016
  • BIO, San Francisco, CA, between June 06-June 09 2016
  • Mastering Medicinal Chemistry conference, Boston, MA, between June 15-June 16 2016

May 2016

CSR Initiative 2015-16

Curadev under its CSR program, sponsored the Impact India’s 172nd Lifeline Express (World’s First Hospital Train) project at Gondia in Maharashtra from May 4 to 25, 2016. The aim of the Lifeline Express is to deliver quality medical and surgical services in rural and remote areas of our country.

April 2016

Dr. David Cameron Pryde appointed Director, R&D of Curadev UK

Dr. David Pryde has joined Curadev as Director R&D bringing his extensive experience in drug discovery to the team. Prior to joining Curadev, Dr. Pryde was at Pfizer for 19 years and led the medicinal chemistry component of programs in several target classes. Dr. Pryde is the author of numerous research publications and patents. He has an honors degree in chemistry from the University of Strathclyde, did his doctoral research at the University of Nottingham and post-doctoral work at Colorado State University. He is also a member of the Royal Society of Chemistry, the organizing committee of the Society for Medicines Research and holds CChem and FRSC status.

American Association for Cancer Research meeting in New Orleans

Curadev and Roche jointly author poster titled: RG70099: A novel, highly potent dual TDO/IDO1 inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment.

January 2016

Curadev announces the incorporation of Curadev UK.